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Introduction
Cyclosporin A (CyA) has been registered in over 124
countries world-wide and is used by more than 50,000
psoriasis patients per year. Human studies using oral
CyA (Sandimmun®) therapy for psoriasis have been in
progress for nearly 13 years, and have confirmed the
clinical efficacy of CyA in this indication. Guidelines
have been developed and adopted for the safe use of
CyA in psoriasis, ̂ '̂  and the relative safety of up to
2 years of therapy has been established, provided
that the guidelines are observed. However, there is
concern regarding the long-term safety of CyA treat-
ment of psoriasis as experience is still limited. Careful
monitoring of all CyA-treated patients is therefore
mandatory.
This meeting was convened to re-examine the cur-
rent recommendations for the use of CyA in psoriasis, in
the light of developments since the last consensus
conference in 1992;^ namely, the growing understand-
ing of psoriasis, changes in clinical practice (including
the use of intermittent short-course therapy), and
increased clinical experience with the new microemul-
sion formulation of CyA (Sandimmun Neoral®). The
principal outcome of the meeting was the creation of an
updated set of recommendations for the use of the CyA
microemulsion in adult psoriatic patients; these recom-
mendations are presented below. It should be noted,
however, that the recommendations are intended only
as guidelines and it is assumed that clinical judgement
will always be exercised.
Who should be treated?
CyA is recommended for psoriatic patients requiring
systemic treatment, and for whom, in the opinions of
both patient and dermatologist, CyA is the most
appropriate available option. The psoriasis should be
of such severity that the risks inherent in this treatment
are justified.
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Indications for particular caution in use
Particular caution and careful clinical judgement are
required in patients with: (i) previous or current malig-
nancies (except basal cell carcinoma); (ii) premalignant
conditions; (iii) primary or secondary immunodeficiency;
(iv) severe hepatic dysfunction; (v) abnormal renal func-
tion; (vi) uncontrolled hypertension; (vii) serious infec-
tion of any type; (viii) tendency to drug or alcohol
abuse; (ix) possible or known pregnancy, and lactation;
(x) inability or lack of will to co-operate with regular
monitoring.
Drug interactions
Particular caution is also required in the use of CyA in
psoriatic patients who are receiving any additional
systemic medication. It is recommended that an
up-to-date reference should be consulted regarding
possible drug interactions whenever a concomitant
medication is used. The following are just some
important examples of the numerous treatments with
recognized potential to interact with CyA; (i) alkylating
agents such as cyclophosphamide (including prior use);
(ii) potentially nephrotoxic agents (e.g. some non-
steroidal anti-infiammatory agents, often prescribed
in psoriatic arthritis); (iii) immunosuppressive therapy;
(iv) radiation therapy; (v) current ultraviolet (UV) irra-
diation and previous over-exposure to UV, including
both solar irradiation and phototherapy (psoralen and
UVA (PUVA) and UVB); (vi) drugs that interfere with
the bioavailability or metabolism of cyclosporin, such
as anticonvulsants, fiuconazole, itraconazole, ketocon-
azole, erythromycin, trimethoprim, diltiazem and ver-
apamil; (vii) drugs such as diclofenac, prednisolone and
lovastatin, the metabolism of which may be affected by
cyclosporin.
Recommended procedure prior to therapy
The patient should be carefully instructed regarding the
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nature and implementation of CyA treatment. Thorough
dermatological and physical examinations should be
performed, with careful attention being paid to mea-
surement of blood pressure. Serum creatinine should be
measured, following a 12-h fast, on at least two sepa-
rate occasions. If these measurements vary by more
than lO^mol/1, further measurements are recom-
mended. The mean value should then be used as the
baseline serum creatinine during subsequent monitor-
ing. Assessment of liver enzymes and serum potassium
and screening for proteinuria are also recommended.
Measurements of bilirubin, magnesium, uric acid and
fasting lipids are often performed but are not considered
obligatory. The patient should be advised to comply
with national recommendations regarding screening
procedures for malignancy (e.g. cervical smear, mammo-
gram, palpation of prostate).
Dosage and treatment regimens
A starting dose of 2-5mg/kg body weight per day
(2-5 mg/kg per day) is recommended for most patients.
It is recommended that the total daily dose is divided
into two doses (morning and evening), although some
dermatologists use a single daily dose. In certain
patients where rapid improvement is considered impor-
tant a higher starting dose may be indicated, but this
should not exceed 5 mg/kg per day.
If improvement in psoriasis has not occurred at 1
month, the CyA dose can be increased gradually, but
should not exceed the maximum of 5 mg/kg per day.
The rate of clearance of psoriasis is related to the
starting dose. At 2-5 mg/kg per day, the improvement
seen at 1 month is sometimes only modest, but it may
nonetheless be appropriate to continue at this dose for
up to 3 months before concluding that a higher dose is
required. If there is insufficient response after 3 months
on the maximum dose of 5 mg/kg per day, CyA should
be discontinued.
When skin lesions improve to an acceptable level, the
CyA dose should be reduced in steps of 0-5-1 mg/kg
body weight to the lowest effective dose; if clinical
improvement continues, CyA should be discontinued
to determine if therapy is still required. Experience
indicates that severe psoriasis recurs when CyA is
stopped, as with other therapies. The length of remis-
sion appears to be a function of both the severity of the
disease and the extent of clearing achieved. Intermittent
therapy is preferable whenever possible, with relapse
managed by the re-introduction of CyA at the previous
effective dose or by initiating a therapy other than CyA.
In some patients, continuous maintenance therapy
may be necessary. The objective of maintenance therapy
is not to totally clear the skin, but to maintain sub-
stantial clinical improvement with the lowest possible
dose of CyA. If a patient experiences serious exacerba-
tion of psoriasis during maintenance therapy, the dose
should be increased sufficiently to control the disease.
Care should be taken to comply with safety guidelines
and the maximum dose should not exceed 5 mg/kg per
day. Every effort should be made to reduce the dose to
the lowest effective level.
If patients have been treated successfully for 2 years,
the decision whether or not to extend therapy should be
based upon the most recent information regarding the
long-term use of CyA in psoriasis. These data continue
to accumulate.
Monitoring of patients during treatment
The use of microemulsified CyA must be carefully
monitored and controlled, in the same way as the
original formulation. Renal function (i.e. serum crea-
tinine) and blood pressure should be monitored every
2 weeks for the first 6 weeks and monthly thereafter.
More frequent monitoring is recommended if the CyA
dose is increased or if there is a rise in serum creatinine
or blood pressure.
In the event that hypertension (mean diastolic blood
pressure >95mmHg on two consecutive occasions)
develops, the dose of CyA may be reduced or the
hypertension may be treated with calcium antagonists
such as nifedipine or isradipine. Diltiazem and ver-
apamil are not recommended because they inhibit
metabolism of CyA. Potassium-sparing diuretics are
probably best avoided as CyA tends to raise serum
potassium levels.
If the serum creatinine rises to more than 30% above
the patient's baseline, the measurement should be
repeated within 2 weeks. Please note that this 30%
refers to a rise above the patient's own baseline, not to
30% above the upper limit of normal serum creatinine for
the measuring laboratory. If the rise is sustained at this
level, the dose of CyA should be reduced by at least
1 mg/kg per day for at least 1 month. If the creatinine
then decreases to less than 30% above the patient's
baseline, treatment can be continued; if not, CyA
therapy should be stopped. Treatment should not then
be recommenced until the creatinine returns to within
10% of the patient's baseline. These guidelines are
summarized in the algorithm in Fig. 1.
If the serum creatinine repeatedly rises to more than
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Serum creatinine rises > 30% above patient's baseline
Repeat measurement within 2 weei<s
i
Creatinine is sustained at > 30% above patient's baseline
i
Reduce CyA dose by at least 1 mg/kg per day
(for at least 1 month)
Creatinine decreases to < 30%
above patient's baseline
i
CyA treatment can be continued





within 10% of patient's
baseline
i
CyA treatment can be
resumed
Figure 1. Steps to follow with rising creatinine.
30% above the patient's baseline when CyA is
re-introduced, then either the CyA should be discon-
tinued and an alternative treatment adopted for the
psoriasis, or advice should be obtained from a nephrol-
ogist. Extreme caution is also required if the serum
creatinine is within 30% of baseline for an individual
but lies outside the normal range, as this may be
indicative of pre-existing renal impairment.
Other side-effects, such as tremor, hypertrichosis,
gingival hyperplasia or nausea, should be recorded. If
these cause concern, the dose should be reduced in steps
or, if necessary, CyA should be discontinued.
Conversion from the original formulation to
the microemulsion formulation
When converting patients from the original CyA
formulation to the microemulsion formulation, a 1:1
dose-conversion strategy is recommended. In the
majority of patients who absorb the original formu-
lation adequately, the absorption of CyA is unlikely
to change post-conversion. However, in patients who
were relatively poor absorbers of CyA from the original
formulation, absorption will increase post-conversion.
As a result, it may be necessary to make subsequent
dose-reductions in these patients to ensure that they are
receiving the lowest effective dose. Dose adjustments
should also be made, as required, to comply with the
safety guidelines above.
Careful safety monitoring is mandatory post-
conversion. Blood pressure and serum creatinine
should be measured prior to conversion and 2, 4 and
8 weeks thereafter. Hypertension or an increase in
serum creatinine should be managed according to the
guidelines above.
Participation and organization of consensus
This consensus took place in Rome, Italy, on 23 June
1996, under the sponsorship of Sandoz Pharma Ltd
(Basel, Switzerland). The co-chairmen were Dr J.Berth-
Jones, Department of Dermatology, Walsgrave Hospital,
Coventry, U.K., and Prof. J.J.Voorhees, Department of
Dermatology, University of Michigan, Ann Arbor,
Michigan, U.S.A.
Other participants were Dr B.Abrams, Sandoz
Research Institute, East Hanover, New Jersey, U.S.A.;
Dr B.R.Allen, Department of Dermatology, University
Hospital, Queen's Medical Centre, Nottingham U.K.;
Prof. J.D.Bos, Department of Dermatology, University
of Amsterdam, Academisch Medisch Centrum, Amster-
dam, The Netherlands; Prof. E.Christophers, Univer-
sitatsklinik, Kiel, Germany; Prof. A.F.Finzi, Institute
of Dermatology, University of Milan, Milan, Italy;
Dr W.Gulliver, Memorial University of Newfoundland,
St John's, Canada; Dr W.Harrison, Sandoz Pharma Ltd,
Basel, Switzerland; Dr V.C.Ho, Division of Dermatology,
University of British Columbia, Vancouver, Canada;
Dr J.Koo, UCSF Psoriasis Treatment Center, University
of California, San Francisco Medical Center, San
Francisco, California, U.S.A.; Dr A.-G.Schmidt, Sandoz
Pharma Ltd, Basel, Switzerland; Dr A.Stutz, Sandoz
Forschungsinstitut, Vienna, Austria.
The authors wish to acknowledge the contribution of
Prof. M.J.Mihatsch in reviewing this report.
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